Cargando…
Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine
The global threat of COVID-19 is continued with no commercially available vaccine or drug yet. While the application of convalescent therapy is usually beneficial, for critically ill patients, the detrimental effect associated with some antibodies is also reported. The immunoglobulin G (IgG) antibod...
Autores principales: | Andualem, Henok, Kiros, Mulugeta, Getu, Sisay, Hailemichael, Wasihun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532904/ https://www.ncbi.nlm.nih.gov/pubmed/33062618 http://dx.doi.org/10.2147/ITT.S274746 |
Ejemplares similares
-
Neopterin: A Promising Candidate Biomarker for Severe COVID-19
por: Hailemichael, Wasihun, et al.
Publicado: (2021) -
Coagulopathy in SARS-CoV-2 Infected Patients: Implication for the Management of COVID-19
por: Getu, Sisay, et al.
Publicado: (2021) -
COVID-19 pandemic: current knowledge about the role of pets and other animals in disease transmission
por: Kiros, Mulugeta, et al.
Publicado: (2020) -
Prevalence and Determinants of Pre-Cancerous Cervical Lesion and Human Papillomavirus Among HIV-Infected and HIV-Uninfected Women in North-West Ethiopia: A Comparative Retrospective Cross-Sectional Study
por: Kiros, Mulugeta, et al.
Publicado: (2021) -
Immunomodulation of COVID‐19 severity by helminth co‐infection: Implications for COVID‐19 vaccine efficacy
por: Akelew, Yibeltal, et al.
Publicado: (2021)